Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Discontinued
Reference number: GID-TA10568
In December 2023, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) confirmed its recommendation to not renew the conditional marketing authorisation for belantamab mafodotin monotherapy (for 5L+ triple class refractory multiple myeloma). GSK has held discussions with the Medicines and Healthcare products Regulatory Agency (MHRA) on the annual renewal of the GB conditional marketing authorisation and have accepted the MHRA’s decision to revoke the conditional marketing authorisation for belantamab mafodotin monotherapy.
NICE will therefore be suspending the technology appraisal and will not reissue final draft guidance. The appeal process also therefore concludes and the appeal hearing that related to the withdrawn final draft guidance will not be rescheduled.